Skip to main content
Top
Published in: Drugs & Aging 11/2004

01-09-2004 | Review Article

The Application of Fuzzy Logic to the Prescription of Antithrombotic Agents in the Elderly

Author: Dr Cathy M. Helgason

Published in: Drugs & Aging | Issue 11/2004

Login to get access

Abstract

The prescription of antithrombotic agents in the elderly depends, to certain degree, on the identity of the unique individual elderly patient. This dependence cannot be captured by viewing the patient as belonging to a group, but rather by viewing age in the context of unique individual biology. This context is historical, physiological, psychological, and time- and location-dependent. The group-based approach to patient therapy is found in evidence-based medicine, typified by the large double-blind randomised clinical trial from which clinical recommendations are defined. An alternative approach to capturing the unique context of each patient is based using fuzzy logic and mathematics. In particular, the fuzzy subsethood theorem of Kosko has direct application here.
A new measure of clinical efficiency, K, derived from the fuzzy subsethood theorem has redefined the clinical significance of age. In particular, the causal role of age in any one patient’s response to therapy is to unique degree for that patient. This is because the causal measure K accounts for the role of known and unknown contextual factors of the patient, most of which are unknown, in defining clinical effect in any specific patient. Thus, we have shown mathematically why ‘age’, or being ‘elderly’, is only one factor to be taken into consideration when therapeutic decisions regarding antithrombotic therapy are made in any given patient. This is contrary to the group-based approach of evidence-based medicine, where age has the same therapeutic significance for all patients. This is because any hypothesis of evidence-based medicine is group-based and cannot be extrapolated to the individual patient. Such extrapolation has to be personalised through the expertise of the physician. The physician takes into account all the factors not considered in any therapeutic group-based trial which apply to his specific patient. These considerations take into account past experience with that patient. An example of the effect of age on the patient and his/her therapeutic context is provided which shows how age affects different patients to different degree using the fuzzy causal measure K. The purpose of this exercise is to show that there is mathematical support for the argument that individualisation of patient therapy by expert decision has measurable clinical significance. What is different here is that measure stick is not probabilistic but fuzzy-mathematic based.
Literature
1.
go back to reference Helgason CM, Malik DS, Cheng S-C, et al. Statistical versus fuzzy measures of interaction in patients with stroke. Neuro-epidemiology 2001; 20: 77–84 Helgason CM, Malik DS, Cheng S-C, et al. Statistical versus fuzzy measures of interaction in patients with stroke. Neuro-epidemiology 2001; 20: 77–84
3.
go back to reference Kosko B. Fuzziness versus probability: the subsethood theorem. In: Kosko B, editor. Neural networks and fuzzy systems: a dynamical approach to machine intelligence. Englewood Cliffs (NJ): Prentice Hall Inc., 1992: 269–74 Kosko B. Fuzziness versus probability: the subsethood theorem. In: Kosko B, editor. Neural networks and fuzzy systems: a dynamical approach to machine intelligence. Englewood Cliffs (NJ): Prentice Hall Inc., 1992: 269–74
4.
go back to reference Helgason CM, Jobe TH. The fuzzy hypercube and causal efficacy: representation of concomitant mechanisms in stroke. Neural Netw 1998; 11: 549–55PubMedCrossRef Helgason CM, Jobe TH. The fuzzy hypercube and causal efficacy: representation of concomitant mechanisms in stroke. Neural Netw 1998; 11: 549–55PubMedCrossRef
5.
go back to reference Helgason CM, Watkins FA, Jobe TH. Measurable differences between sequential and parallel diagnostic decision processes for determining stroke subtype: a representation of interacting pathologies. Thromb Haemost 2002; 88: 210–2PubMed Helgason CM, Watkins FA, Jobe TH. Measurable differences between sequential and parallel diagnostic decision processes for determining stroke subtype: a representation of interacting pathologies. Thromb Haemost 2002; 88: 210–2PubMed
6.
go back to reference Helgason CM, Jobe TH. Perception-based reasoning and fuzzy cardinality provide direct measures of causality sensitive to initial conditions in the individual patient. Int J Computational Cognition 2003; 1: 79–104 Helgason CM, Jobe TH. Perception-based reasoning and fuzzy cardinality provide direct measures of causality sensitive to initial conditions in the individual patient. Int J Computational Cognition 2003; 1: 79–104
7.
go back to reference Helgason CM, Jobe TH. How the number of dimensions affects fuzzy causal measures of vitamin therapy for hyperhomocysteinemia in stroke patients. Proceedings of the Annual Meeting of the North American Fuzzy Information Processing Society; 2003 Jul 24–26: Chicago, 218–21 Helgason CM, Jobe TH. How the number of dimensions affects fuzzy causal measures of vitamin therapy for hyperhomocysteinemia in stroke patients. Proceedings of the Annual Meeting of the North American Fuzzy Information Processing Society; 2003 Jul 24–26: Chicago, 218–21
8.
go back to reference Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1986; 89 (2 Suppl.): 2–3S Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1986; 89 (2 Suppl.): 2–3S
9.
go back to reference The European Stroke Initiative Executive Committee and the EUSI Writing Committee. European stroke initiative recommendations for stroke management: update 2003. Cerebrovasc Dis 2003; 16: 311–37CrossRef The European Stroke Initiative Executive Committee and the EUSI Writing Committee. European stroke initiative recommendations for stroke management: update 2003. Cerebrovasc Dis 2003; 16: 311–37CrossRef
10.
go back to reference Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692–711PubMedCrossRef Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692–711PubMedCrossRef
12.
go back to reference Reiffel JA. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation? Curr Opin Cardiol 2004; 19: 58–63PubMedCrossRef Reiffel JA. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation? Curr Opin Cardiol 2004; 19: 58–63PubMedCrossRef
13.
go back to reference Ximelagatran is as effective as standard enoxaparin sodium plus warfarin therapy for venous thromboembolism (VTE). Inpharma Weekly 2003 Jul; 1(1397): 9 Ximelagatran is as effective as standard enoxaparin sodium plus warfarin therapy for venous thromboembolism (VTE). Inpharma Weekly 2003 Jul; 1(1397): 9
14.
go back to reference Johansson LC, Frison L, Logren U, et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003; 42: 381–92PubMedCrossRef Johansson LC, Frison L, Logren U, et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003; 42: 381–92PubMedCrossRef
15.
go back to reference Barro S, Marin R, editors. Fuzzy logic in medicine. In: Kacprzyk J, series editor. Studies in fuzziness and soft computing series. Vol. 83. Heidelberg: Physica-Verlag, 2002: 83 Barro S, Marin R, editors. Fuzzy logic in medicine. In: Kacprzyk J, series editor. Studies in fuzziness and soft computing series. Vol. 83. Heidelberg: Physica-Verlag, 2002: 83
16.
go back to reference Teodorescu H-N, Kandel A, Jain L. Fuzzy and neuro-fuzzy systems in medicine. Boca Raton (FL): CRC Press LLC, 1999 Teodorescu H-N, Kandel A, Jain L. Fuzzy and neuro-fuzzy systems in medicine. Boca Raton (FL): CRC Press LLC, 1999
17.
go back to reference Mordeson JN, Malik DS, Cheng S-C. Fuzzy mathematics in medicine. Heidelberg: Physica Verlag, 2000 Mordeson JN, Malik DS, Cheng S-C. Fuzzy mathematics in medicine. Heidelberg: Physica Verlag, 2000
18.
go back to reference Szczepaniak PS, Lisboa Paolo JG. Fuzzy systems in medicine. Vol. 41. Heidelberg: Physica Verlag, 2000CrossRef Szczepaniak PS, Lisboa Paolo JG. Fuzzy systems in medicine. Vol. 41. Heidelberg: Physica Verlag, 2000CrossRef
19.
Metadata
Title
The Application of Fuzzy Logic to the Prescription of Antithrombotic Agents in the Elderly
Author
Dr Cathy M. Helgason
Publication date
01-09-2004
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 11/2004
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200421110-00003

Other articles of this Issue 11/2004

Drugs & Aging 11/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine